. . . . . . . . . "cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms otitis media streptococcus pneumoniae haemophilus influenzae streptococcus pyogenes note b haemophilus influenzae in vitro lower respiratory tract infections streptococcus pneumoniae haemophilus influenzae streptococcus pyogenes note b haemophilus influenzae in vitro pharyngitis and tonsillitis streptococcus pyogenes note urinary tract infections escherichia coli proteus mirabilis klebsiella skin and skin structure infections staphylococcus aureus streptococcus pyogenes appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor to reduce the development of drug resistant bacteria and maintain the effectiveness of cefaclor for oral suspension and other antibacterial drugs cefaclor for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy" . . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "e2vlEHWjCWhhij+qyvNtmA0CjEWguKeGXOAJNtnzHkLQFiw7tRoKS2JaEkWQ+VcOhJFxPSwnGkjR1iWIiIGvBe3qVq4NvyrwjOnVqemSN+7S27ayqGfYf+aR8fyxaCxlDl7HZiEbAu78LQQciRFv59dSDvVHontAwx85yKDJfh4=" . . "2021-06-13T12:09:47.600+02:00"^^ . . . . .